ライフサイエンスコーパス: CMAP

1 CMAP amplitude showed a linear decline over the course o

2 CMAP results indicated statistically significant improve

3 m compound motor action potential amplitude (CMAP) studies, and results correlated with SMN2 copy, ag

4 isease onset restored myelination, MNCV, and CMAP almost to levels seen in WT animals.

5 e repressed (CCR2, VpreB, lambda5, SLPI, and CMAP/Cystatin7) genes, respectively, were bona fide NF-k

6 relations were identified between TIMPSI and CMAP in SMA infants.

7 which includes optimization of the backbone CMAP potential to achieve good balance between different

8 The baseline CMAP amplitude was 946.5+/-609.2 mV and decreased by 13.

9 -helical bias present in the former CHARMM22/CMAP energy function, is shown to result in improved coo

10 the potential energy parameter set CHARMM22/CMAP correctly yield an alpha-helix, in contrast to simu

11 Concordant CMAP amplitude-and-area decrements of >20% allow more re

12 In contrast, CMAP parameters derived by fitting to a vacuum quantum m

13 With the Complement Map Database (CMAP), we have created a novel and easily accessible res

14 Recording of diaphragmatic CMAP using a catheter positioned in a subdiaphragmatic h

15 r units using objective electrophysiological CMAP and MUNE values as biomarkers will guide and improv

16 Hindlimb CMAP and MUNE demonstrated strong correlations with plan

17 8 of 132 patients (13.6%), a 30% decrease in CMAP amplitude occurred and cryoablation was discontinue

18 If a 30% decrease in CMAP amplitude was observed, cryoapplication was discont

19 If a 30% drop in CMAP amplitude was observed, ablation was discontinued w

20 ients and was preceded by a 30% reduction in CMAP amplitude in all.

21 In 82% of cases, this reduction in CMAP amplitude occurred during right superior PV isolati

22 right-sided ablation, a >/=30% reduction in CMAP amplitude occurred in 49 patients (24.5%).

23 ly, clinically relevant biomarkers including CMAP and MUNE are responsive to SMN restoration, and abr

24 In the first approach, Connectivity Map (CMAP) analysis of these TFs and their target networks ou

25 loped algorithms to search Connectivity Map (CMAP) data for medicines that modulate AD-associated gen

26 The Connectivity Map (CMAP) represents an unprecedented resource to study the

27 show how by combining the Connectivity Map (CMAP) with ChEA, we can rank pairs of compounds to be us

28 Maximum CMAP at the time of the initial assessment was most pred

29 han 3 correlated with lower MUNE and maximum CMAP values (p < 0.0001) and worse functional outcomes.

30 Changes in MUNE and maximum CMAP values over time were dependent on age, SMA type, a

31 MUNE and maximum CMAP values were distinct among SMA subtypes (p < 0.05).

32 Age-dependent decline in MUNE and maximum CMAP was apparent in both SMA 1 (p < 0.0001) and SMA 2 (

33 However, a decline in maximum CMAP over time was apparent in SMA2 subjects (p = 0.049)

34 Reliable recording of CMAP before ablation was feasible in 50 of 57 patients (

35 Recovery of CMAP amplitude after discontinuing cryoablation took <60

36 Each time, recovery of CMAP amplitude took <60 s.

37 The mean value of CMAP amplitude was 639.7+/-240.5 microV; mean variation

38 rical corrections introduced in the original CMAP to reproduce folded protein structures-corrections

39 In 44 of 50 patients, CMAP amplitude remained constant during cryoapplication.

40 ly reduced compound muscle action potential (CMAP) amplitude values.

41 aphragmatic compound motor action potential (CMAP) amplitude was recorded via a quadripolar catheter

42 lated with compound muscle action potential (CMAP) amplitudes of median, ulnar, peroneal, and tibial

43 Compound motor action potential (CMAP) amplitudes were significantly reduced in the soleu

44 Compound muscle action potential (CMAP) and motor unit (MU) number estimation (MUNE) are w

45 nd reduced compound muscle action potential (CMAP) and motor unit number estimation (MUNE), as in hum

46 (MFS) and compound muscle action potential (CMAP) decreased rapidly in SMA infants, whereas MFS in a

47 om-maximum-compound muscle action potential (CMAP) in patients with Andersen-Tawil syndrome.

48 ent of the compound muscle action potential (CMAP) on repetitive stimulation at 3 Hz, and increased j

49 aphragmatic compound motor action potential (CMAP) via a quadripolar catheter positioned in a hepatic

50 ease in the compound motor action potential (CMAP).

51 d reduced compound muscle action potentials (CMAP) in patients.

52 d motor and sensory nerve action potentials (CMAPs and SNAPs), distal weakness, sensory loss and decr

53 litude of compound muscle action potentials (CMAPs) from ulnar nerve stimulation in the right and lef

54 , reduced compound muscle action potentials (CMAPs), and compromised neuromuscular transmission.

55 h the Colorado Mammography Advocacy Project (CMAP).

56 xhibited MG-like symptoms, including reduced CMAP and impaired neuromuscular transmission.

57 In analogy we refined CMAP and MUNE methods for assessing spinal MU input in t

58 Repeated CMAP and MUNE recordings are robust (coefficients of var

59 expression database/connectivity map (SPIED/CMAP), to generate a catalogue of small molecules that c

60 Stable CMAP amplitudes were achieved before ablation in 132 of

61 c phrenic nerve monitoring using the surface CMAP is reliable, easy to perform, and offers an early w

62 es the inclusion of many-body effects in the CMAP.

63 zed using the comparative genetic map viewer CMAP.

64 In these patients, muscle weakness, CMAP amplitudes and motor unit number estimates correlat